Literature DB >> 21421997

Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease.

Philip Michael Gaughwin1, Maciej Ciesla, Nayana Lahiri, Sarah J Tabrizi, Patrik Brundin, Maria Björkqvist.   

Abstract

Huntington's disease (HD) is a devastating, neurodegenerative condition, which lacks effective treatment. Normal Huntingtin (HTT) and mutant Huntingtin (mHTT) are expressed in multiple tissues and can alter transcription of microRNAs (miRs). Importantly, miRs are present in a bio-stable form in human peripheral blood plasma and have recently been shown to be useful biomarkers in other diseases. We therefore sought to identify potential miR biomarkers of HD that are present in, and have functional consequences for, neuronal and non-neuronal tissues. In a cell line over-expressing mHTT-Exon-1, miR microarray analysis was used to identify candidate miRs. We then examined their presence and bio-stability in control and HD plasma. We found that miR-34b is significantly elevated in response to mHTT-Exon-1, and its blockade alters the toxicity of mHTT-Exon-1 in vitro. We also show that miR-34b is detectable in plasma from small input volumes and is insensitive to freeze-thaw-induced RNA degradation. Interestingly, miR-34b is significantly elevated in plasma from HD gene carriers prior to symptom onset. This is the first study suggesting that plasma miRs might be used as biomarkers for HD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21421997     DOI: 10.1093/hmg/ddr111

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  81 in total

Review 1.  Functions of noncoding RNAs in neural development and neurological diseases.

Authors:  Shan Bian; Tao Sun
Journal:  Mol Neurobiol       Date:  2011-10-04       Impact factor: 5.590

Review 2.  Role of viruses, prions and miRNA in neurodegenerative disorders and dementia.

Authors:  Sayed Sartaj Sohrab; Mohd Suhail; Ashraf Ali; Mohammad Amjad Kamal; Azamal Husen; Fahim Ahmad; Esam Ibraheem Azhar; Nigel H Greig
Journal:  Virusdisease       Date:  2018-09-29

3.  miR-34b-a novel plasma marker for Huntington disease?

Authors:  Vanisha Parekh
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

4.  miR-25 alleviates polyQ-mediated cytotoxicity by silencing ATXN3.

Authors:  Fengzhen Huang; Li Zhang; Zhe Long; Zhao Chen; Xuan Hou; Chunrong Wang; Huirong Peng; Junling Wang; Jiada Li; Ranhui Duan; Kun Xia; De-Maw Chuang; Beisha Tang; Hong Jiang
Journal:  FEBS Lett       Date:  2014-11-20       Impact factor: 4.124

Review 5.  Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases.

Authors:  Xue-Feng Jin; Ning Wu; Lv Wang; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2013-04-30       Impact factor: 5.046

Review 6.  miRNAs at the interface of cellular stress and disease.

Authors:  Anna Emde; Eran Hornstein
Journal:  EMBO J       Date:  2014-05-27       Impact factor: 11.598

7.  A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

Authors:  Jose Luis López-Sendón Moreno; Juan García Caldentey; Patricia Trigo Cubillo; Carolina Ruiz Romero; Guillermo García Ribas; M A Alonso Alonso Arias; María Jesús García de Yébenes; Rosa María Tolón; Ismael Galve-Roperh; Onintza Sagredo; Sara Valdeolivas; Eva Resel; Silvia Ortega-Gutierrez; María Laura García-Bermejo; Javier Fernández Ruiz; Manuel Guzmán; Justo García de Yébenes Prous
Journal:  J Neurol       Date:  2016-05-09       Impact factor: 4.849

Review 8.  Pathogenetic and therapeutic applications of microRNAs in major depressive disorder.

Authors:  Yogesh Dwivedi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-14       Impact factor: 5.067

Review 9.  MicroRNAs in depression and suicide: Recent insights and future perspectives.

Authors:  Yogesh Dwivedi
Journal:  J Affect Disord       Date:  2018-07-24       Impact factor: 4.839

Review 10.  Noncoding RNAs in neurodegeneration.

Authors:  Evgenia Salta; Bart De Strooper
Journal:  Nat Rev Neurosci       Date:  2017-08-17       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.